Generic Verdeso Availability

Verdeso is a brand name of desonide topical, approved by the FDA in the following formulation(s):

VERDESO (desonide - aerosol, foam;topical)

  • Manufacturer: AQUA PHARMS
    Approval date: September 19, 2006
    Strength(s): 0.05% [RLD]

Has a generic version of Verdeso been approved?

No. There is currently no therapeutically equivalent version of Verdeso available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Verdeso. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Mousse composition
    Patent 6,730,288
    Issued: May 4, 2004
    Inventor(s): Albert Zorko; Abram
    Assignee(s): Connetics Australia Pty Ltd
    A pharmaceutical aerosol foam composition including an effective amount of a pharmaceutically active ingredient; an occlusive agent; an aqueous solvent; and an organic cosolvent, the pharmaceutically active ingredient being insoluble in both water and the occlusive agent; the occlusive agent being present in an amount sufficient to form an occlusive layer on the skin, in use.
    Patent expiration dates:
    • September 8, 2019
      Drug product
  • Mousse composition
    Patent 7,029,659
    Issued: April 18, 2006
    Inventor(s): Abram; Albert Zorko
    Assignee(s): Connetics Australia Pty Ltd.
    A topical mousse composition including an occlusive agent; an aqueous solvent; and an organic cosolvent, wherein the occlusive agent is present in an amount sufficient to form an occlusive layer on the skin.
    Patent expiration dates:
    • September 8, 2019
      Drug product
  • Microemulsion process and composition
    Patent 8,460,641
    Issued: June 11, 2013
    Assignee(s): Stiefel Research Australia Pty Ltd
    An oil-in-water microemulsion or sub-micron emulsion composition for dermal delivery of at least one pharmaceutically active ingredient, comprising: a first part including at least one occlusive agent and one or more lipophilic surfactants dispersed throughout a second part including water and at least one hydrophilic surfactant, and a non-surfactant amphiphilic type compound, pharmaceutically active ingredient, and water. It has been found that if a non-surfactant amphiphilic type compound is added together with the second part as would conventionally be the case, a microemulsion or sub-micron emulsion is not formed, by adding the so called third part, phase assembly occurs at a lower temperature than would be expected and moreover, this phase appears to assist in maintaining the microemulsion or sub-micron emulsion characteristics of the formulation during storage at normal temperatures.
    Patent expiration dates:
    • November 5, 2028
      Drug product


Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.